Not available
Quote | Santhera Pharms Hldgs Ltd (OTCMKTS:SPHDF)
Last: | $11.70 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $11.70 |
High: | $0 |
Low: | $0 |
Volume: | 59 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Santhera Pharms Hldgs Ltd (OTCMKTS:SPHDF)
2024-03-31 04:50:00 ET Summary South Korea’s AriBio out-licensed China rights for AR1001, an Alzheimer’s disease candidate, in an agreement worth up to $770M. AnHeart Therapeutics, a New York-Hangzhou biopharma, will become part of Nuvation Bio (NYSE: NUVB) of New Yo...
Pratteln, Switzerland, March 27, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that the China National Medical Products Administration (NMPA) has accepted for priority review the new drug application (NDA) for vamorolone in Duchenne muscular dystrophy (DMD) which was submitted...
Message Board Posts | Santhera Pharms Hldgs Ltd (OTCMKTS:SPHDF)
Subject | By | Source | When |
---|---|---|---|
$SPHDF is one step ahead in DMD submission! | beebob77 | investorshub | 11/04/2014 12:37:30 PM |
$SPHDF recent news/filings | stocktrademan | investorshub | 08/19/2014 2:26:36 PM |
News, Short Squeeze, Breakout and More Instantly...
Santhera Pharms Hldgs Ltd Company Name:
SPHDF Stock Symbol:
OTCMKTS Market:
Pratteln, Switzerland, March 27, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that the China National Medical Products Administration (NMPA) has accepted for priority review the new drug application (NDA) for vamorolone in Duchenne muscular dystrophy (DMD) which was submitted...
AGAMREE® is U.S. FDA approved and now available in the United States for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older This follows the first commercial launch of AGAMREE in Germany in January 2024 by Santhera AGAMREE is the first DMD...
Results from 112 patients with DMD who completed the study confirm maintenance of efficacy and benefits in safety and tolerability of treatment with vamorolone over 48 weeks AGAMREE® has shown safety benefits in patients switching from standard of care corticosteroids in terms of rec...